Syndecan-1在结直肠癌中的表达与EGFR表达、K-Ras突变及化疗疗效相关性分析

中国临床药理学与治疗学 ›› 2017, Vol. 22 ›› Issue (8): 927-932.

Syndecan-1在结直肠癌中的表达与EGFR表达、K-Ras突变及化疗疗效相关性分析

原少斐，朱林佳，郑维锷，梁美珍

温州医科大学附属第三医院肿瘤中心，温州 325200，浙江

收稿日期:2016-12-30 修回日期:2017-02-14 出版日期:2017-08-26 发布日期:2017-08-18
通讯作者: 梁美珍，女，博士，副教授，研究方向：肿瘤精准治疗。 Tel:0577-65866340 E-mail: kitty.linjia@163.com
作者简介:原少斐，男，硕士，讲师，研究方向：肿瘤化学治疗。 Tel:0577-65866342 E-mail: ysf1004@163.com
基金资助:
浙江省科技计划项目（2016L10320）

Relationship of Syndecan-1 and EGFR expression, K-Ras gene mutations and response to FOLFOX in advanced colorectal carcinoma

YUAN Shaofei, ZHU Linjia, ZHENG Weie, LIANG Meizhen

Oncology Department, the Third Affiliated Hospital, Wenzhou Medical University, Wenzhou 325200, Zhejiang, China

Received:2016-12-30 Revised:2017-02-14 Online:2017-08-26 Published:2017-08-18

摘要/Abstract

摘要：

目的: 探讨结直肠癌中Syndecan-1的表达与表皮生长因子受体(epidermal growth factorreceptor，EGFR)表达、K-Ras基因突变及化疗疗效的关系。方法: 利用免疫组织化学法检测160例晚期结直肠癌患者中Syndecan-1的表达情况，分析其与患者临床病理特征、分子标志物及FOLFOX方案化疗疗效的相关性。结果: 所有患者中有41例(25.6%)Syndecan-1表达阳性，111例(69.4%)EGFR表达阳性；Syndecan-1的表达与EGFR表达显著相关（P<0.05）；与K-Ras基因突变无相关性（P>0.05）；Syndecan-1表达阳性患者的化疗有效率56.1%，阴性患者为40.3%（P<0.05），Syndecan-1表达阳性患者的中位无疾病进展时间为8.8个月，而阴性患者为7.2个月（P<0.05）。结论: Syndecan-1的表达对结直肠癌进展及判断预后有一定的临床价值，且与常用FOLFOX化疗方案的疗效有相关性。

关键词: 结直肠癌, Syndecan-1, 表皮生长因子受体, K-Ras, 化疗疗效

Abstract:

AIM: To investigate the relationship of Syndecan-1 and EGFR expression, K-Ras gene mutations and response to FOLFOX in advanced colorectal carcinoma. METHODS: 160 surgical specimens of advanced colorectal carcinoma from patients consecutively treated between June 2009 and December 2014 at our hospital were collected. Immunohistochemistry method was used to screen for Syndecan-1 expression. The relationship between Syndecan-1 expression and various clinicopathological parameters, molecular markers, curative effect of FOLFOX was analyzed.RESULTS:Syndecan-1 expression was identified in the cancer cells of 41 (25.6%) colorectal cancer cases, epidermal growth factor receptor expression in 111(69.4%) colorectal cancer cases. The expression of syndecan-1 was statistically correlated with the expression of epidermal growth factor receptor (P<0.05). However, it was not significantly correlated with K-Ras mutation (P>0.05). Patients with over-expressed Syndecan-1 exhibited better efficacy on FOLFOX solution than patients presented negative Syndecan-1 expression (56.1% vs. 40.3%, P<0.05); Patients with over-expressed Syndecan-1 also presented longer median time to progress (8.8 month vs. 7.2 month, P<0.05). CONCLUSION: The expression of Syndecan-1 is referential for evaluating the progress and the prognosis of colorectal cancer. And the expression of Syndecan-1 is statistically correlated with curative effect of FOLFOX regimens.

Key words: colorectal carcinoma, Syndecan-1, EGFR, K-RAS, curative effect of chemotherapy

中图分类号:

R735.3

原少斐，朱林佳，郑维锷，梁美珍. Syndecan-1在结直肠癌中的表达与EGFR表达、K-Ras突变及化疗疗效相关性分析[J]. 中国临床药理学与治疗学, 2017, 22(8): 927-932.

YUAN Shaofei, ZHU Linjia, ZHENG Weie, LIANG Meizhen. Relationship of Syndecan-1 and EGFR expression, K-Ras gene mutations and response to FOLFOX in advanced colorectal carcinoma[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(8): 927-932.

参考文献

［1］Teng YH, Aquino RS, Park PW. Molecular functions of Syndecan-1 in disease［J］. Matrix Biol, 2012, 31:3-16.
［2］Akl MR, Nagpal P, Ayoub NM, et al. Molecular and clinical profiles of Syndecan-1 in solid and hematological cancer for prognosis and precision medicine［J］.Oncotarget, 2015, 6(30):28693-28715.
［3］Pasqualon T, Pruessmeyer J, Weidenfeld S, et al. A transmembrane C-terminal fragment of Syndecan-1 is generated by the metalloproteinase ADAM17 and promotes lung epithelial tumor cell migration and lung metastasis formation［J］.Cell Mol Life Sci, 2015,72(19):3783-3801.
［4］Dobre M, Dinu DE, Panaitescu E, et al. K-Ras gene mutations-prognostic factor in colorectal cancer［J］ ? Rom J Morphol Embryo, 2015, 56(2 Suppl):671-678.
［5］Alves S, Castro L, Fernandes MS.Colorectal cancer-related mutant K-Ras alleles function as positive regulators of autophagy［J］.Oncotarget, 2015, 6(31):30787-30802.
［6］Barresi V, Bonetti LR, Bettelli S. K-Ras, N-Ras, B-RAF mutations and high counts of poorly differentiated clusters of neoplastic cells in colorectal cancer: observational analysis of 175 cases［J］.Pathology, 2015, 47(6):551-556.
［7］Spindler KL, Pallisgaard N, Appelt AL,et al. Clinical utility of K-Ras status in circulating plasma DNA compared to archival tumour tissue from patients with metastatic colorectal cancer treated with anti-epidermal growth factor receptor therapy［J］.Eur J Cancer, 2015, 51(17):2678-2685.
［8］Marino A, Caliolo C, Sponziello F, et al. Panitumumab after progression on cetuximab in K-RAS wild-type metastaticcolorectal cancer patients: a single institution experience［J］.Tumori, 2015,101 (5):524-528.
［9］Kusumoto T, Kodama J, Seki N, et al. Clinical significance of Syndecan-1 and versican expression in human epithelial ovariancancer［J］. Oncol Rep, 2010, 23(9): 917-925.
［10］周霞辉, 吴成就,肖乐东,等.焦磷酸测序技术检测K-RAS基因突变方法的建立［J］.中国临床药理学与治疗学, 2015, 20(4): 430-434.
［11］Lim GH, Tan PH, Jara-Lazaro AR, et al.Syndecan-1 is a potential biomarker for triple-positive breast carcinomas in Asian women with correlation to survival［J］.Singapore Med J,2014,55(9):468-472.
［12］Xu Y，Yuan J，Zhang Z，et al．Syndeean-1 expression in human glioma is correlated with advanced tumor progression and poor prognosis［J］.Mol Biol Rep, 2012,39(9):8979-8985．
［13］李明武,韩国宏.分子靶向药物治疗晚期胆道肿瘤的研究进展［J］. 临床肝胆病杂志,2014(11):1212-1216.
［14］Phua LC, Ng HW, Yeo AH, et al. Prevalence of K-Ras, B-RAF, PI3K and EGFR mutations among Asian patients with metastatic colorectal cancer［J］.Oncol Lett, 2015, 10(4):2519-2526.
［15］Osumi H, Shinozaki E, Osako M, et al. Cetuximab treatment for metastatic colorectal cancer with K-RAS p.G13D mutations improves progression-free survival［J］.Mol Clin Oncol, 2015, 3(5):1053-1057.
［16］Yazdi MH, Faramarzi MA, Nikfar S, et al. A comprehensive review of clinical trials on EGFR inhibitors such as cetuximab and panitumumab as monotherapy and in combination for treatment of metastatic colorectal cancer［J］.Avicenna J Med Biotechnol, 2015, 7(4):134-144.

[1]	石大伟, 郑晓永, 靳晓丹, 赵晓曼, 陈杰, 杜幸军. XPC基因多态性rs2228001对接受卡培他滨为基础辅助化疗的结直肠癌患者预后的影响[J]. 中国临床药理学与治疗学, 2023, 28(4): 391-399.
[2]	卫真真, 隋华, 姜宇朗, 孙明瑜, 闫化茹, 王子元. 左金丸联合西妥昔单抗诱导KRAS突变肠癌细胞铁死亡作用研究[J]. 中国临床药理学与治疗学, 2023, 28(2): 130-137.
[3]	吴先闯, 刘瑜新, 牛玉季, 赫锦锦, 乔辉, 张蕾蕾. 肝细胞癌中DCLK1转录调控的机制研究[J]. 中国临床药理学与治疗学, 2023, 28(11): 1241-1246.
[4]	周广琛, 刘怡希, 郑云. 结直肠癌和microRNA：研究进展[J]. 中国临床药理学与治疗学, 2022, 27(5): 575-587.
[5]	李岩岩, 方骁杰, 尹鑫, 孙曦, 饶春晖. circZNF124通过靶向miR-4262调控结直肠癌SW620细胞增殖、迁移及侵袭的机制研究[J]. 中国临床药理学与治疗学, 2022, 27(11): 1231-1239.
[6]	鲁琼, 朱海宏, 戚听听, 李国华, 滕欣琪, 屈强, 屈健. OCTN2基因多态性影响结直肠癌奥沙利铂化疗敏感性[J]. 中国临床药理学与治疗学, 2021, 26(4): 401-407.
[7]	沈龙德, 李爱禄, 李丽春, 吴银银, 沈龙源, 江秋霞, 贺锦曦, 吴志芬, 余黎吉, 张晓红. 姜黄素对大鼠子宫内膜异位症影响的实验研究#br#[J]. 中国临床药理学与治疗学, 2020, 25(8): 862-868.
[8]	张德志, 刘猛, 朱少功, 刘桂举, 季节. XELOX方案对比卡培他滨单药方案在老年结直肠癌患者术后辅助化疗中的疗效及安全性探讨[J]. 中国临床药理学与治疗学, 2020, 25(8): 926-936.
[9]	王子元, 孙明瑜. 长链非编码RNA在结直肠癌耐药中的研究进展[J]. 中国临床药理学与治疗学, 2020, 25(7): 796-802.
[10]	石莉莉, 刘兴安, 单国用. 阿帕替尼后线治疗标准方案失败的晚期结直肠癌的疗效和安全性及疗效预测因子的初步分析[J]. 中国临床药理学与治疗学, 2020, 25(12): 1388-1394.
[11]	李荣振，梅家转，夏云展，季节. 真实世界中R0切除术后结直肠癌患者接受卡培他滨为基础辅助化疗的预后影响因素及安全性探讨[J]. 中国临床药理学与治疗学, 2019, 24(6): 704-711.
[12]	乔大伟，李玉芳，肖云，姜礼双，卜平. 半枝莲抗结直肠癌及其转移机制研究进展[J]. 中国临床药理学与治疗学, 2019, 24(3): 332-336.
[13]	白艳，郑晓永，杨雅阁，方立峰. 程序性死亡配体1基因遗传变异对术后结直肠癌患者接受5-FU为基础辅助化疗预后的影响[J]. 中国临床药理学与治疗学, 2019, 24(2): 180-187.
[14]	李晓洁，张胜威，王华胜，王东，梅家转，邓业巍. VEGF-A基因多态性对接受氟尿嘧啶为基础辅助化疗的结直肠癌患者预后的影响[J]. 中国临床药理学与治疗学, 2018, 23(8): 900-904.
[15]	胡洋，李智星，王果，朱院山. 长链非编码RNA与结直肠癌耐药的研究进展[J]. 中国临床药理学与治疗学, 2018, 23(4): 456-463.